Back to Results

A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, anti-CD3 Monoclonal Antibody, in Children and Adolescents with Newly Diagnosed Type 1 Diabetes (T1D)

Study

Is this Study for You?

Let's Get Started!

Details
Age

Child

Type of Study

Treatment

Locations

Barbara Davis Center
Outpatient CTRC
UCD Barbara Davis Center
University of Colorado Hospital

Principal Investigator
Kimber Simmons,  MD, MPH/MSPH

Kimber Simmons, MD, MPH/MSPH

Study ID

Protocol Number: 19-0489

More information available at ClinicalTrials.gov: NCT03875729

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers